FDA wins experimental drugs decision

Share this article:
The Washington, DC Court of Appeals has ruled in the FDA's favor that terminally ill patients have no "fundamental right 'deeply rooted in this nation's history and tradition'" to have access to experimental drugs. Late last year, the FDA won a petition to have the full US Court of Appeals for DC reconsider a ruling that mentally competent terminally ill patients should have access to post-phase I investigational drugs if there are no government-approved alternative treatments available.

The court agreed 2-1 that patients have a right to unapproved drugs, and said an earlier court opinion had erred.

Speaking on an FDLI audio conference later, FDA deputy chief counsel Jeff Senger said that accessing these drugs is not a fundamental constitutional right and thus the FDA needs only a “rational” basis for its regulatory drug development policy.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.